

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Elaine Alison IRVING et al.
Appl. No. : 10/550,363
Filed : September 19, 2005
Title : Therapeutical Use of Anti-myelin Associated Glycoprotein
(MAG)
Antibodies
Docket: : PB60024USw

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH
37 C.F.R. § 1.821-1.825

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821 (g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted

25 Aug 06
Date

Virginia G. Campen
Virginia G. Campen
Attorney of Record, Reg. No. 37,092

GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398 US
Phone: 919-483-1012; Facsimile: 919-483-7988

Express Mail Label No.: EV332131076US
Date of Mailing: 8/28/06

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

Patty Wilson
Patty Wilson